Correlation between bradykinin concentration and blood pressure during Rheocarna therapy: A single-center case series.

Introduction: A novel LDL (low-density lipoprotein) apheresis therapeutic option, Rheocarna, has garnered attention as an alternative therapy for chronic limb-threating ischemia (CLTI). Bradykinin-mediated vasodilation is involved in the effects of LDL apheresis and a decrease in blood pressure (BP), but the changes in bradykinin concentration during Rheocarna therapy are unknown.

Methods: The study involved patients with CLTI treated with Rheocarna at our hospital, from April 2022 to August 2023.